Journal of experimental & clinical cancer research : CR
-
J. Exp. Clin. Cancer Res. · Mar 1998
Comparative StudyTropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
Tropisetron is a novel selective antagonist of the type-3 serotonin (5-HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of > 100 mg/m2 has a high emetogenic potential. This study was designed to determine whether a single intravenous administration of tropisetron could prevent acute nausea and vomiting in patients treated with high dose epirubicin. ⋯ Headache was the most common adverse event reported in 3 patients (7.5%) and constipation in 2 patients (5%). Interestingly, patients with a negative experience of nausea and vomiting during pregnancy and those treated for metastatic disease, had a better control of chemotherapy-induced nausea and vomiting. In conclusion, a single 5 mg i.v. dose of tropisetron is safe and effective in preventing acute emesis in patients treated with high dose epirubicin.
-
J. Exp. Clin. Cancer Res. · Jun 1997
Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells.
Effect of Iscador, an extract from semiparasitic plant Viscum Album on the inhibition of lung metastatic colony formation induced by B16F10 melanoma cells was studied in mice. Simultaneous administration of drug (1.66 mg/dose) and B16F10 melanoma cells could inhibit lung nodule formation by 92%. ⋯ Lung hydroxyproline and serum sialic acid levels were also lower in the tumour bearing animals treated with Viscum Album. The animals treated with simultaneous drug administration had an increase of 71.34% in their life span.
-
J. Exp. Clin. Cancer Res. · Mar 1997
Multicentre experience with combined hyperthermia and radiation therapy in the treatment of superficially located non-Hodgkin's lymphomas.
The combination of Radiation Therapy (RT) and Hyperthermia (HT) has proved to be an effective treatment for a wide variety of superficially located recurrences of different tumors, particularly those arising in previously irradiated areas. Few studies on the use of HT in the management of lymphomatous diseases have so far obtained interesting results. Eight patients with Non Hodgkin Lymphomas (LNH) - 4 with cutaneous lymphomas and 4 with nodal recurrences after RT-Chemotherapy (CHT) treatment treated in three different Italian institutions with combined RT and HT are here reported. ⋯ All patients tolerated well the HT treatment, and in all cases average intratumoral temperatures were >42 degrees, with 3 out of 10 treated sites achieving the goal of average temperatures >42.5%. One patient, with recurrent NHL, is disease-free after 24 months from completion of combined therapy. Our results seem to confirm previous experiences, suggesting a role of HT/RT not only for palliative purposes in cutaneous lymphomas, but also as an adjunct to radiotherapy alone in selected patients with superficially located recurrences.